nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A4—Thiotepa—urinary bladder cancer	0.0794	0.328	CbGbCtD
Ethosuximide—CYP2E1—Etoposide—urinary bladder cancer	0.071	0.294	CbGbCtD
Ethosuximide—CYP3A5—Etoposide—urinary bladder cancer	0.0552	0.228	CbGbCtD
Ethosuximide—CYP3A4—Etoposide—urinary bladder cancer	0.0215	0.089	CbGbCtD
Ethosuximide—CYP3A4—Doxorubicin—urinary bladder cancer	0.0147	0.0607	CbGbCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—urinary bladder cancer	0.00225	0.00626	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—CNTN2—urinary bladder cancer	0.00222	0.0062	CbGpPWpGaD
Ethosuximide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00216	0.00601	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00206	0.00573	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00205	0.00572	CbGpPWpGaD
Ethosuximide—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00205	0.0057	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—HPGDS—urinary bladder cancer	0.00199	0.00555	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—GSTZ1—urinary bladder cancer	0.00193	0.00539	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—GSTT1—urinary bladder cancer	0.00193	0.00539	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00191	0.00531	CbGpPWpGaD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00186	0.00517	CbGpPWpGaD
Ethosuximide—Headache—Mitomycin—urinary bladder cancer	0.00185	0.00463	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTO2—urinary bladder cancer	0.00183	0.00511	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—NAT1—urinary bladder cancer	0.00183	0.00511	CbGpPWpGaD
Ethosuximide—Mental disorder—Thiotepa—urinary bladder cancer	0.00183	0.00458	CcSEcCtD
Ethosuximide—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00183	0.00458	CcSEcCtD
Ethosuximide—Malnutrition—Thiotepa—urinary bladder cancer	0.00182	0.00456	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00181	0.00504	CbGpPWpGaD
Ethosuximide—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.0018	0.0045	CcSEcCtD
Ethosuximide—Pancytopenia—Etoposide—urinary bladder cancer	0.00178	0.00446	CcSEcCtD
Ethosuximide—Nausea—Mitomycin—urinary bladder cancer	0.00175	0.00439	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—urinary bladder cancer	0.00174	0.00485	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.00174	0.00435	CcSEcCtD
Ethosuximide—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00173	0.00433	CcSEcCtD
Ethosuximide—Urethral disorder—Gemcitabine—urinary bladder cancer	0.00172	0.00432	CcSEcCtD
Ethosuximide—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00168	0.00421	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—UGT2B7—urinary bladder cancer	0.00168	0.00467	CbGpPWpGaD
Ethosuximide—Hiccups—Epirubicin—urinary bladder cancer	0.00168	0.0042	CcSEcCtD
Ethosuximide—Agitation—Thiotepa—urinary bladder cancer	0.00167	0.00419	CcSEcCtD
Ethosuximide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00166	0.00416	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00166	0.00415	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00165	0.00461	CbGpPWpGaD
Ethosuximide—Leukopenia—Thiotepa—urinary bladder cancer	0.00163	0.00408	CcSEcCtD
Ethosuximide—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.00162	0.00405	CcSEcCtD
Ethosuximide—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00161	0.00403	CcSEcCtD
Ethosuximide—Urethral disorder—Cisplatin—urinary bladder cancer	0.00161	0.00402	CcSEcCtD
Ethosuximide—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00159	0.00398	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CNTN2—urinary bladder cancer	0.00159	0.00442	CbGpPWpGaD
Ethosuximide—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00158	0.00397	CcSEcCtD
Ethosuximide—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00157	0.00394	CcSEcCtD
Ethosuximide—Agranulocytosis—Etoposide—urinary bladder cancer	0.00156	0.00391	CcSEcCtD
Ethosuximide—Hiccups—Doxorubicin—urinary bladder cancer	0.00155	0.00388	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00154	0.00385	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—urinary bladder cancer	0.00154	0.00428	CbGpPWpGaD
Ethosuximide—Eye disorder—Cisplatin—urinary bladder cancer	0.00153	0.00383	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—CYP4B1—urinary bladder cancer	0.00151	0.0042	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00149	0.00415	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00148	0.00371	CcSEcCtD
Ethosuximide—Immune system disorder—Cisplatin—urinary bladder cancer	0.00148	0.00371	CcSEcCtD
Ethosuximide—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00148	0.0037	CcSEcCtD
Ethosuximide—Urethral disorder—Etoposide—urinary bladder cancer	0.00147	0.00369	CcSEcCtD
Ethosuximide—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00146	0.00365	CcSEcCtD
Ethosuximide—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00146	0.00365	CcSEcCtD
Ethosuximide—Mental disability—Epirubicin—urinary bladder cancer	0.00145	0.00364	CcSEcCtD
Ethosuximide—Skin disorder—Thiotepa—urinary bladder cancer	0.00144	0.00361	CcSEcCtD
Ethosuximide—Malnutrition—Cisplatin—urinary bladder cancer	0.00143	0.00357	CcSEcCtD
Ethosuximide—Erythema multiforme—Etoposide—urinary bladder cancer	0.00142	0.00355	CcSEcCtD
Ethosuximide—Anorexia—Thiotepa—urinary bladder cancer	0.00142	0.00354	CcSEcCtD
Ethosuximide—Eye disorder—Etoposide—urinary bladder cancer	0.0014	0.00351	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTZ1—urinary bladder cancer	0.0014	0.0039	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.0014	0.00389	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—urinary bladder cancer	0.00139	0.00388	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00138	0.00385	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00138	0.00384	CbGpPWpGaD
Ethosuximide—Muscle spasms—Cisplatin—urinary bladder cancer	0.00137	0.00343	CcSEcCtD
Ethosuximide—Leukopenia—Gemcitabine—urinary bladder cancer	0.00137	0.00343	CcSEcCtD
Ethosuximide—Immune system disorder—Etoposide—urinary bladder cancer	0.00136	0.0034	CcSEcCtD
Ethosuximide—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00135	0.00339	CcSEcCtD
Ethosuximide—Leukopenia—Fluorouracil—urinary bladder cancer	0.00135	0.00337	CcSEcCtD
Ethosuximide—Mental disability—Doxorubicin—urinary bladder cancer	0.00135	0.00337	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTP1—urinary bladder cancer	0.00134	0.00373	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GSTO2—urinary bladder cancer	0.00133	0.0037	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—NAT1—urinary bladder cancer	0.00133	0.0037	CbGpPWpGaD
Ethosuximide—Lethargy—Methotrexate—urinary bladder cancer	0.00133	0.00332	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.00132	0.00369	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.00132	0.00369	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—SRC—urinary bladder cancer	0.00132	0.00369	CbGpPWpGaD
Ethosuximide—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00132	0.00369	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00132	0.00368	CbGpPWpGaD
Ethosuximide—Somnolence—Thiotepa—urinary bladder cancer	0.00132	0.00331	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00131	0.00365	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00131	0.00364	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—urinary bladder cancer	0.0013	0.00362	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00129	0.00324	CcSEcCtD
Ethosuximide—Decreased appetite—Thiotepa—urinary bladder cancer	0.00129	0.00323	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00128	0.00321	CcSEcCtD
Ethosuximide—Fatigue—Thiotepa—urinary bladder cancer	0.00128	0.00321	CcSEcCtD
Ethosuximide—Leukopenia—Cisplatin—urinary bladder cancer	0.00128	0.0032	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—urinary bladder cancer	0.00126	0.00351	CbGpPWpGaD
Ethosuximide—Muscle spasms—Etoposide—urinary bladder cancer	0.00126	0.00315	CcSEcCtD
Ethosuximide—Lethargy—Epirubicin—urinary bladder cancer	0.00124	0.00311	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—urinary bladder cancer	0.00124	0.00311	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTM1—urinary bladder cancer	0.00123	0.00343	CbGpPWpGaD
Ethosuximide—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00123	0.00307	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—urinary bladder cancer	0.00122	0.00306	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00121	0.00304	CcSEcCtD
Ethosuximide—CYP3A43—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00121	0.00338	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00121	0.00338	CbGpPWpGaD
Ethosuximide—Skin disorder—Gemcitabine—urinary bladder cancer	0.00121	0.00304	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.00121	0.00338	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00121	0.00302	CcSEcCtD
Ethosuximide—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.0012	0.00302	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.0012	0.00334	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00119	0.00333	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—urinary bladder cancer	0.00119	0.00333	CbGpPWpGaD
Ethosuximide—Anorexia—Gemcitabine—urinary bladder cancer	0.00119	0.00298	CcSEcCtD
Ethosuximide—Urticaria—Thiotepa—urinary bladder cancer	0.00118	0.00295	CcSEcCtD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00118	0.00328	CbGpPWpGaD
Ethosuximide—Breast disorder—Methotrexate—urinary bladder cancer	0.00117	0.00294	CcSEcCtD
Ethosuximide—Abdominal pain—Thiotepa—urinary bladder cancer	0.00117	0.00294	CcSEcCtD
Ethosuximide—Anorexia—Fluorouracil—urinary bladder cancer	0.00117	0.00293	CcSEcCtD
Ethosuximide—Leukopenia—Etoposide—urinary bladder cancer	0.00117	0.00293	CcSEcCtD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00116	0.00324	CbGpPWpGaD
Ethosuximide—Lethargy—Doxorubicin—urinary bladder cancer	0.00115	0.00288	CcSEcCtD
Ethosuximide—Ataxia—Epirubicin—urinary bladder cancer	0.00114	0.00286	CcSEcCtD
Ethosuximide—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00114	0.00286	CcSEcCtD
Ethosuximide—Skin disorder—Cisplatin—urinary bladder cancer	0.00113	0.00283	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—urinary bladder cancer	0.00111	0.00279	CcSEcCtD
Ethosuximide—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00111	0.00278	CcSEcCtD
Ethosuximide—Somnolence—Gemcitabine—urinary bladder cancer	0.00111	0.00278	CcSEcCtD
Ethosuximide—Anorexia—Cisplatin—urinary bladder cancer	0.00111	0.00278	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00111	0.00277	CcSEcCtD
Ethosuximide—Breast disorder—Epirubicin—urinary bladder cancer	0.0011	0.00275	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—urinary bladder cancer	0.0011	0.00305	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00109	0.00274	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00109	0.00305	CbGpPWpGaD
Ethosuximide—Somnolence—Fluorouracil—urinary bladder cancer	0.00109	0.00273	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.00109	0.00304	CbGpPWpGaD
Ethosuximide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00109	0.00272	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00108	0.0027	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00108	0.003	CbGpPWpGaD
Ethosuximide—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00108	0.0027	CcSEcCtD
Ethosuximide—Fatigue—Gemcitabine—urinary bladder cancer	0.00108	0.0027	CcSEcCtD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00108	0.003	CbGpPWpGaD
Ethosuximide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00107	0.00267	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—urinary bladder cancer	0.00107	0.00267	CcSEcCtD
Ethosuximide—Asthenia—Thiotepa—urinary bladder cancer	0.00107	0.00267	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00106	0.00265	CcSEcCtD
Ethosuximide—Ataxia—Doxorubicin—urinary bladder cancer	0.00106	0.00265	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	0.00104	0.0029	CbGpPWpGaD
Ethosuximide—Eosinophilia—Epirubicin—urinary bladder cancer	0.00104	0.00261	CcSEcCtD
Ethosuximide—Skin disorder—Etoposide—urinary bladder cancer	0.00104	0.00259	CcSEcCtD
Ethosuximide—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00103	0.00257	CcSEcCtD
Ethosuximide—Breast disorder—Doxorubicin—urinary bladder cancer	0.00102	0.00255	CcSEcCtD
Ethosuximide—Anorexia—Etoposide—urinary bladder cancer	0.00102	0.00255	CcSEcCtD
Ethosuximide—Diarrhoea—Thiotepa—urinary bladder cancer	0.00102	0.00254	CcSEcCtD
Ethosuximide—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00101	0.00283	CbGpPWpGaD
Ethosuximide—Decreased appetite—Cisplatin—urinary bladder cancer	0.00101	0.00253	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00101	0.00252	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—NAT2—urinary bladder cancer	0.001	0.0028	CbGpPWpGaD
Ethosuximide—Drowsiness—Methotrexate—urinary bladder cancer	0.001	0.00251	CcSEcCtD
Ethosuximide—Pancytopenia—Epirubicin—urinary bladder cancer	0.000999	0.0025	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000993	0.00249	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00099	0.00276	CbGpPWpGaD
Ethosuximide—Dizziness—Thiotepa—urinary bladder cancer	0.000982	0.00246	CcSEcCtD
Ethosuximide—Urticaria—Fluorouracil—urinary bladder cancer	0.000976	0.00244	CcSEcCtD
Ethosuximide—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000963	0.00241	CcSEcCtD
Ethosuximide—Haematuria—Methotrexate—urinary bladder cancer	0.000955	0.00239	CcSEcCtD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000955	0.00266	CbGpPWpGaD
Ethosuximide—Weight decreased—Epirubicin—urinary bladder cancer	0.000951	0.00238	CcSEcCtD
Ethosuximide—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000951	0.00265	CbGpPWpGaD
Ethosuximide—Somnolence—Etoposide—urinary bladder cancer	0.000948	0.00237	CcSEcCtD
Ethosuximide—Vomiting—Thiotepa—urinary bladder cancer	0.000944	0.00236	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000942	0.00262	CbGpPWpGaD
Ethosuximide—Drowsiness—Epirubicin—urinary bladder cancer	0.000938	0.00235	CcSEcCtD
Ethosuximide—Rash—Thiotepa—urinary bladder cancer	0.000936	0.00234	CcSEcCtD
Ethosuximide—Dermatitis—Thiotepa—urinary bladder cancer	0.000935	0.00234	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000935	0.00234	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—urinary bladder cancer	0.000931	0.0026	CbGpPWpGaD
Ethosuximide—Headache—Thiotepa—urinary bladder cancer	0.00093	0.00233	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000929	0.00233	CcSEcCtD
Ethosuximide—Decreased appetite—Etoposide—urinary bladder cancer	0.000927	0.00232	CcSEcCtD
Ethosuximide—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000924	0.00231	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000921	0.00231	CcSEcCtD
Ethosuximide—Fatigue—Etoposide—urinary bladder cancer	0.00092	0.0023	CcSEcCtD
Ethosuximide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000905	0.00227	CcSEcCtD
Ethosuximide—Asthenia—Gemcitabine—urinary bladder cancer	0.000896	0.00224	CcSEcCtD
Ethosuximide—Haematuria—Epirubicin—urinary bladder cancer	0.000894	0.00224	CcSEcCtD
Ethosuximide—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000888	0.00222	CcSEcCtD
Ethosuximide—Nausea—Thiotepa—urinary bladder cancer	0.000882	0.00221	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—urinary bladder cancer	0.000882	0.00221	CcSEcCtD
Ethosuximide—Weight decreased—Doxorubicin—urinary bladder cancer	0.00088	0.0022	CcSEcCtD
Ethosuximide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000875	0.00219	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000872	0.00218	CcSEcCtD
Ethosuximide—Drowsiness—Doxorubicin—urinary bladder cancer	0.000867	0.00217	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00086	0.00215	CcSEcCtD
Ethosuximide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000858	0.00215	CcSEcCtD
Ethosuximide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000855	0.00214	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00085	0.00213	CcSEcCtD
Ethosuximide—Urticaria—Etoposide—urinary bladder cancer	0.000847	0.00212	CcSEcCtD
Ethosuximide—Abdominal pain—Etoposide—urinary bladder cancer	0.000843	0.00211	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—urinary bladder cancer	0.00084	0.0021	CcSEcCtD
Ethosuximide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00084	0.0021	CcSEcCtD
Ethosuximide—Asthenia—Cisplatin—urinary bladder cancer	0.000835	0.00209	CcSEcCtD
Ethosuximide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000831	0.00208	CcSEcCtD
Ethosuximide—Haematuria—Doxorubicin—urinary bladder cancer	0.000827	0.00207	CcSEcCtD
Ethosuximide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000827	0.00207	CcSEcCtD
Ethosuximide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000825	0.00207	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—GSTZ1—urinary bladder cancer	0.000821	0.00229	CbGpPWpGaD
Ethosuximide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000812	0.00203	CcSEcCtD
Ethosuximide—Dizziness—Fluorouracil—urinary bladder cancer	0.000812	0.00203	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000811	0.00203	CcSEcCtD
Ethosuximide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00081	0.00203	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—HPGDS—urinary bladder cancer	0.000803	0.00224	CbGpPWpGaD
Ethosuximide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000797	0.00199	CcSEcCtD
Ethosuximide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000796	0.00199	CcSEcCtD
Ethosuximide—Vomiting—Gemcitabine—urinary bladder cancer	0.000794	0.00199	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—urinary bladder cancer	0.000788	0.00197	CcSEcCtD
Ethosuximide—Rash—Gemcitabine—urinary bladder cancer	0.000788	0.00197	CcSEcCtD
Ethosuximide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000787	0.00197	CcSEcCtD
Ethosuximide—Eye disorder—Epirubicin—urinary bladder cancer	0.000787	0.00197	CcSEcCtD
Ethosuximide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000786	0.00197	CcSEcCtD
Ethosuximide—Malnutrition—Methotrexate—urinary bladder cancer	0.000783	0.00196	CcSEcCtD
Ethosuximide—Headache—Gemcitabine—urinary bladder cancer	0.000783	0.00196	CcSEcCtD
Ethosuximide—Vomiting—Fluorouracil—urinary bladder cancer	0.000781	0.00196	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTT1—urinary bladder cancer	0.000779	0.00217	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTO2—urinary bladder cancer	0.000778	0.00217	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—NAT1—urinary bladder cancer	0.000778	0.00217	CbGpPWpGaD
Ethosuximide—Rash—Fluorouracil—urinary bladder cancer	0.000774	0.00194	CcSEcCtD
Ethosuximide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000774	0.00194	CcSEcCtD
Ethosuximide—Headache—Fluorouracil—urinary bladder cancer	0.000769	0.00193	CcSEcCtD
Ethosuximide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000769	0.00193	CcSEcCtD
Ethosuximide—Asthenia—Etoposide—urinary bladder cancer	0.000765	0.00192	CcSEcCtD
Ethosuximide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000765	0.00192	CcSEcCtD
Ethosuximide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000763	0.00191	CcSEcCtD
Ethosuximide—Immune system disorder—Epirubicin—urinary bladder cancer	0.00076	0.0019	CcSEcCtD
Ethosuximide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000759	0.0019	CcSEcCtD
Ethosuximide—Nausea—Gemcitabine—urinary bladder cancer	0.000742	0.00186	CcSEcCtD
Ethosuximide—Vomiting—Cisplatin—urinary bladder cancer	0.00074	0.00185	CcSEcCtD
Ethosuximide—Mental disorder—Epirubicin—urinary bladder cancer	0.000737	0.00185	CcSEcCtD
Ethosuximide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000736	0.00184	CcSEcCtD
Ethosuximide—Rash—Cisplatin—urinary bladder cancer	0.000734	0.00184	CcSEcCtD
Ethosuximide—Dermatitis—Cisplatin—urinary bladder cancer	0.000733	0.00184	CcSEcCtD
Ethosuximide—Malnutrition—Epirubicin—urinary bladder cancer	0.000733	0.00183	CcSEcCtD
Ethosuximide—Diarrhoea—Etoposide—urinary bladder cancer	0.00073	0.00183	CcSEcCtD
Ethosuximide—Nausea—Fluorouracil—urinary bladder cancer	0.00073	0.00183	CcSEcCtD
Ethosuximide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000728	0.00182	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—NAT2—urinary bladder cancer	0.000727	0.00203	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000726	0.00202	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000717	0.002	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000716	0.00199	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—UGT2B7—urinary bladder cancer	0.000712	0.00198	CbGpPWpGaD
Ethosuximide—Dizziness—Etoposide—urinary bladder cancer	0.000705	0.00177	CcSEcCtD
Ethosuximide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000704	0.00176	CcSEcCtD
Ethosuximide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000703	0.00176	CcSEcCtD
Ethosuximide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000702	0.00176	CcSEcCtD
Ethosuximide—Leukopenia—Methotrexate—urinary bladder cancer	0.000701	0.00175	CcSEcCtD
Ethosuximide—Nausea—Cisplatin—urinary bladder cancer	0.000692	0.00173	CcSEcCtD
Ethosuximide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000682	0.00171	CcSEcCtD
Ethosuximide—Vomiting—Etoposide—urinary bladder cancer	0.000678	0.0017	CcSEcCtD
Ethosuximide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000678	0.0017	CcSEcCtD
Ethosuximide—Agitation—Epirubicin—urinary bladder cancer	0.000673	0.00169	CcSEcCtD
Ethosuximide—Rash—Etoposide—urinary bladder cancer	0.000673	0.00168	CcSEcCtD
Ethosuximide—Dermatitis—Etoposide—urinary bladder cancer	0.000672	0.00168	CcSEcCtD
Ethosuximide—Headache—Etoposide—urinary bladder cancer	0.000668	0.00167	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000662	0.00166	CcSEcCtD
Ethosuximide—Leukopenia—Epirubicin—urinary bladder cancer	0.000656	0.00164	CcSEcCtD
Ethosuximide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000652	0.00163	CcSEcCtD
Ethosuximide—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00065	0.00181	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP4B1—urinary bladder cancer	0.000641	0.00179	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000641	0.00179	CbGpPWpGaD
Ethosuximide—Nausea—Etoposide—urinary bladder cancer	0.000634	0.00159	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000627	0.00157	CcSEcCtD
Ethosuximide—Agitation—Doxorubicin—urinary bladder cancer	0.000623	0.00156	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—urinary bladder cancer	0.000621	0.00155	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000619	0.00155	CcSEcCtD
Ethosuximide—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000616	0.00172	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000616	0.00172	CbGpPWpGaD
Ethosuximide—Anorexia—Methotrexate—urinary bladder cancer	0.000609	0.00152	CcSEcCtD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000607	0.00169	CbGpPWpGaD
Ethosuximide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000607	0.00152	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—SLC19A1—urinary bladder cancer	0.000605	0.00169	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—NCOR1—urinary bladder cancer	0.000594	0.00166	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PRSS3—urinary bladder cancer	0.00059	0.00164	CbGpPWpGaD
Ethosuximide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000586	0.00147	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—HPGDS—urinary bladder cancer	0.000581	0.00162	CbGpPWpGaD
Ethosuximide—Skin disorder—Epirubicin—urinary bladder cancer	0.000581	0.00145	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.00058	0.00162	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000573	0.00144	CcSEcCtD
Ethosuximide—Anorexia—Epirubicin—urinary bladder cancer	0.00057	0.00143	CcSEcCtD
Ethosuximide—Somnolence—Methotrexate—urinary bladder cancer	0.000568	0.00142	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTT1—urinary bladder cancer	0.000564	0.00157	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000563	0.00157	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000563	0.00157	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000556	0.00155	CbGpPWpGaD
Ethosuximide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000555	0.00139	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000552	0.00138	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—urinary bladder cancer	0.000551	0.00138	CcSEcCtD
Ethosuximide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000543	0.00136	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	0.00054	0.0015	CbGpPWpGaD
Ethosuximide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000537	0.00135	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000532	0.00148	CbGpPWpGaD
Ethosuximide—Somnolence—Epirubicin—urinary bladder cancer	0.000532	0.00133	CcSEcCtD
Ethosuximide—Anorexia—Doxorubicin—urinary bladder cancer	0.000527	0.00132	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000522	0.00131	CcSEcCtD
Ethosuximide—Decreased appetite—Epirubicin—urinary bladder cancer	0.00052	0.0013	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—RHOA—urinary bladder cancer	0.000518	0.00144	CbGpPWpGaD
Ethosuximide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000516	0.00129	CcSEcCtD
Ethosuximide—Fatigue—Epirubicin—urinary bladder cancer	0.000516	0.00129	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—urinary bladder cancer	0.000508	0.00127	CcSEcCtD
Ethosuximide—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000507	0.00141	CbGpPWpGaD
Ethosuximide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000505	0.00126	CcSEcCtD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.0005	0.00139	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	0.000496	0.00138	CbGpPWpGaD
Ethosuximide—Somnolence—Doxorubicin—urinary bladder cancer	0.000492	0.00123	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000489	0.00136	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000489	0.00122	CcSEcCtD
Ethosuximide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000481	0.0012	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—ERBB2—urinary bladder cancer	0.00048	0.00134	CbGpPWpGaD
Ethosuximide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000478	0.0012	CcSEcCtD
Ethosuximide—Fatigue—Doxorubicin—urinary bladder cancer	0.000477	0.00119	CcSEcCtD
Ethosuximide—Urticaria—Epirubicin—urinary bladder cancer	0.000475	0.00119	CcSEcCtD
Ethosuximide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000473	0.00118	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—TYMP—urinary bladder cancer	0.000471	0.00131	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000471	0.00118	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CDK4—urinary bladder cancer	0.000469	0.00131	CbGpPWpGaD
Ethosuximide—Asthenia—Methotrexate—urinary bladder cancer	0.000458	0.00115	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000452	0.00113	CcSEcCtD
Ethosuximide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000441	0.0011	CcSEcCtD
Ethosuximide—Urticaria—Doxorubicin—urinary bladder cancer	0.00044	0.0011	CcSEcCtD
Ethosuximide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000437	0.0011	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000437	0.00109	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000437	0.00122	CbGpPWpGaD
Ethosuximide—Asthenia—Epirubicin—urinary bladder cancer	0.000429	0.00107	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—NAT2—urinary bladder cancer	0.000426	0.00119	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—PPARG—urinary bladder cancer	0.000426	0.00119	CbGpPWpGaD
Ethosuximide—Dizziness—Methotrexate—urinary bladder cancer	0.000423	0.00106	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—MMP9—urinary bladder cancer	0.000412	0.00115	CbGpPWpGaD
Ethosuximide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000409	0.00102	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CREBBP—urinary bladder cancer	0.000409	0.00114	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000408	0.00102	CcSEcCtD
Ethosuximide—Vomiting—Methotrexate—urinary bladder cancer	0.000406	0.00102	CcSEcCtD
Ethosuximide—Rash—Methotrexate—urinary bladder cancer	0.000403	0.00101	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—urinary bladder cancer	0.000402	0.00101	CcSEcCtD
Ethosuximide—Headache—Methotrexate—urinary bladder cancer	0.0004	0.001	CcSEcCtD
Ethosuximide—Asthenia—Doxorubicin—urinary bladder cancer	0.000397	0.000994	CcSEcCtD
Ethosuximide—Dizziness—Epirubicin—urinary bladder cancer	0.000395	0.00099	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTP1—urinary bladder cancer	0.000391	0.00109	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.00039	0.00109	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000386	0.00107	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000385	0.00107	CbGpPWpGaD
Ethosuximide—Vomiting—Epirubicin—urinary bladder cancer	0.00038	0.000952	CcSEcCtD
Ethosuximide—Nausea—Methotrexate—urinary bladder cancer	0.00038	0.00095	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—SRC—urinary bladder cancer	0.000379	0.00106	CbGpPWpGaD
Ethosuximide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000379	0.000948	CcSEcCtD
Ethosuximide—Rash—Epirubicin—urinary bladder cancer	0.000377	0.000944	CcSEcCtD
Ethosuximide—Dermatitis—Epirubicin—urinary bladder cancer	0.000377	0.000943	CcSEcCtD
Ethosuximide—Headache—Epirubicin—urinary bladder cancer	0.000375	0.000938	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—RHOA—urinary bladder cancer	0.00037	0.00103	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—RRM2—urinary bladder cancer	0.000368	0.00103	CbGpPWpGaD
Ethosuximide—Dizziness—Doxorubicin—urinary bladder cancer	0.000366	0.000916	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTM1—urinary bladder cancer	0.000359	0.001	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000358	0.000999	CbGpPWpGaD
Ethosuximide—Nausea—Epirubicin—urinary bladder cancer	0.000355	0.000889	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000354	0.000987	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000354	0.000985	CbGpPWpGaD
Ethosuximide—Vomiting—Doxorubicin—urinary bladder cancer	0.000352	0.000881	CcSEcCtD
Ethosuximide—Rash—Doxorubicin—urinary bladder cancer	0.000349	0.000873	CcSEcCtD
Ethosuximide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000349	0.000873	CcSEcCtD
Ethosuximide—Headache—Doxorubicin—urinary bladder cancer	0.000347	0.000868	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—ERBB2—urinary bladder cancer	0.000342	0.000954	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—HPGDS—urinary bladder cancer	0.000341	0.00095	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ENO2—urinary bladder cancer	0.000341	0.00095	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000337	0.00094	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000333	0.000927	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—EGFR—urinary bladder cancer	0.000333	0.000927	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000331	0.000921	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTT1—urinary bladder cancer	0.000331	0.000921	CbGpPWpGaD
Ethosuximide—Nausea—Doxorubicin—urinary bladder cancer	0.000329	0.000823	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—KRAS—urinary bladder cancer	0.000314	0.000876	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000313	0.000873	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000313	0.000873	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP9—urinary bladder cancer	0.000294	0.000818	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	0.000287	0.000799	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—EP300—urinary bladder cancer	0.000278	0.000776	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—NQO1—urinary bladder cancer	0.000275	0.000765	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—SRC—urinary bladder cancer	0.000271	0.000755	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00027	0.000752	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—HRAS—urinary bladder cancer	0.000267	0.000744	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000262	0.000729	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	0.000258	0.000719	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	0.000244	0.000679	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	0.000239	0.000667	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000239	0.000666	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	0.000238	0.000662	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—EGFR—urinary bladder cancer	0.000237	0.000661	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTP1—urinary bladder cancer	0.000229	0.000638	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	0.000227	0.000633	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NAT1—urinary bladder cancer	0.000227	0.000633	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000227	0.000631	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000227	0.000631	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TNF—urinary bladder cancer	0.000226	0.00063	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—KRAS—urinary bladder cancer	0.000224	0.000625	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—TYMS—urinary bladder cancer	0.000213	0.000594	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTM1—urinary bladder cancer	0.000211	0.000587	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—NCOR1—urinary bladder cancer	0.000211	0.000587	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	0.000208	0.000579	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000207	0.000577	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GPX1—urinary bladder cancer	0.000202	0.000562	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ERCC2—urinary bladder cancer	0.000198	0.000552	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—HRAS—urinary bladder cancer	0.000191	0.000531	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—TYMP—urinary bladder cancer	0.00019	0.000529	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	0.000187	0.000521	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000187	0.00052	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—MTHFR—urinary bladder cancer	0.000186	0.000519	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000181	0.000505	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000179	0.000498	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	0.000177	0.000492	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.000176	0.000491	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	0.000172	0.000479	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NAT2—urinary bladder cancer	0.000172	0.000478	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.000172	0.000478	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000167	0.000464	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000164	0.000458	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PPARG—urinary bladder cancer	0.000151	0.00042	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—RRM2—urinary bladder cancer	0.000148	0.000413	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CREBBP—urinary bladder cancer	0.000145	0.000404	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—TYMP—urinary bladder cancer	0.000138	0.000383	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	0.000137	0.000383	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ENO2—urinary bladder cancer	0.000137	0.000383	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—TYMP—urinary bladder cancer	0.000137	0.000382	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	0.000133	0.000371	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NAT2—urinary bladder cancer	0.000124	0.000347	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NAT2—urinary bladder cancer	0.000124	0.000346	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTGS2—urinary bladder cancer	0.000119	0.000331	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000111	0.00031	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NQO1—urinary bladder cancer	0.000111	0.000308	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—RRM2—urinary bladder cancer	0.000107	0.000299	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—RRM2—urinary bladder cancer	0.000107	0.000299	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.000105	0.000293	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.000105	0.000293	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTEN—urinary bladder cancer	0.000104	0.000288	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	9.94e-05	0.000277	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ENO2—urinary bladder cancer	9.94e-05	0.000277	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	9.92e-05	0.000276	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ENO2—urinary bladder cancer	9.92e-05	0.000276	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—EP300—urinary bladder cancer	9.87e-05	0.000275	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	9.64e-05	0.000269	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	9.63e-05	0.000268	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	9.62e-05	0.000268	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	9.23e-05	0.000257	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.67e-05	0.000242	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—TYMS—urinary bladder cancer	8.58e-05	0.000239	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	8.48e-05	0.000236	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	8.48e-05	0.000236	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.19e-05	0.000228	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GPX1—urinary bladder cancer	8.12e-05	0.000226	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NQO1—urinary bladder cancer	8.01e-05	0.000223	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NQO1—urinary bladder cancer	8e-05	0.000223	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.98e-05	0.000222	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	7.97e-05	0.000222	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	7.5e-05	0.000209	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	6.68e-05	0.000186	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	6.67e-05	0.000186	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.38e-05	0.000178	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—TYMS—urinary bladder cancer	6.21e-05	0.000173	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—TYMS—urinary bladder cancer	6.2e-05	0.000173	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	6.14e-05	0.000171	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	6.14e-05	0.000171	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	6.13e-05	0.000171	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	6.13e-05	0.000171	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PPARG—urinary bladder cancer	6.08e-05	0.000169	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GPX1—urinary bladder cancer	5.88e-05	0.000164	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GPX1—urinary bladder cancer	5.87e-05	0.000164	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	5.84e-05	0.000163	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	5.78e-05	0.000161	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.77e-05	0.000161	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	5.76e-05	0.000161	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	5.43e-05	0.000151	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	5.42e-05	0.000151	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.98e-05	0.000139	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	4.78e-05	0.000133	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.61e-05	0.000129	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.61e-05	0.000129	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.47e-05	0.000125	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PPARG—urinary bladder cancer	4.4e-05	0.000123	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.39e-05	0.000122	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	4.23e-05	0.000118	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	4.22e-05	0.000118	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTEN—urinary bladder cancer	4.17e-05	0.000116	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—EP300—urinary bladder cancer	3.98e-05	0.000111	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.72e-05	0.000104	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	3.46e-05	9.65e-05	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.46e-05	9.63e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.1e-05	8.64e-05	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTEN—urinary bladder cancer	3.02e-05	8.42e-05	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.01e-05	8.4e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.88e-05	8.03e-05	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—EP300—urinary bladder cancer	2.88e-05	8.03e-05	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.87e-05	8.01e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.85e-05	7.94e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.85e-05	7.94e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.73e-05	7.61e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.68e-05	7.47e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.52e-05	7.02e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.04e-05	5.69e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.96e-05	5.47e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.61e-05	4.48e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.4e-05	3.9e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.34e-05	3.72e-05	CbGpPWpGaD
